Audio Transcript Auto-generated
- 00:01 - 00:06
So with the immune stimulatory effect of C P G. O. D. N. Can provide.
- 00:06 - 00:11
You may be a great use as an ad prevention vaccine which can be a timely topic.
- 00:11 - 00:16
Since we are still facing the pandemic with new variants of covid 19.
- 00:16 - 00:19
Vaccination is still the safest and most
- 00:19 - 00:23
cost effective medical method of disease prevention.
- 00:23 - 00:23
Today
- 00:24 - 00:30
the necessity for adjuvants that can induce and sustain immune responses against
- 00:30 - 00:36
antigens of interest is a crucial factor in developing such vaccines.
- 00:39 - 00:40
C P G. O. D.
- 00:40 - 00:46
N improves antigen absorption by professional antigen presenting cells.
- 00:47 - 00:50
Also it triggers the antigen presenting
- 00:50 - 00:53
cell functional maturation and generates a
- 00:53 - 00:57
cytokine chemokine micro environment supportive of
- 00:57 - 01:00
antigens specific immunity via T.
- 01:00 - 01:06
L. R. Stimulation. So all of which contribute to vaccine immunogenicity.
- 01:06 - 01:12
So here the L. R. Nine is activated by the un methylated CPG.
- 01:12 - 01:16
All ego dioxin nucleotide will lead to
- 01:16 - 01:19
the generation of pro inflammatory side two kinds
- 01:20 - 01:23
and generating a th one response.
- 01:23 - 01:26
So when the immune system is exposed to
- 01:26 - 01:30
the vaccination and adjuvant this affects are maximized.
- 01:30 - 01:35
So studies in various animal models show that CPG audience
- 01:35 - 01:41
improve and balance immune responses when administered in combination.
- 01:41 - 01:44
We currently use vaccine as events.
- 01:44 - 01:47
So clinical experiments are currently being conducted
- 01:47 - 01:50
to determine the adjuvant potential of C.
- 01:50 - 01:51
B. G. S.
- 01:52 - 01:52
Yeah
- 01:53 - 01:57
the first study is improving the immunogenicity
- 01:57 - 02:00
of pneumococcal conjugate vaccine in HIV infected
- 02:00 - 02:03
adults with a tall like receptor nine
- 02:03 - 02:08
agonist adjuvant a randomized controlled trial.
- 02:08 - 02:12
So people infected with human immunodeficiency
- 02:12 - 02:15
virus they are frequently hyper responsive.
- 02:15 - 02:17
So it is suggested to
- 02:17 - 02:20
At CPG 7909
- 02:21 - 02:23
Which is the toll like receptor nine agonies.
- 02:24 - 02:29
Uh In addition to the seven villain pneumococcal conjugate vaccine and
- 02:29 - 02:33
they say that it will improve the immunogenicity in H.
- 02:33 - 02:34
I. V. Positive
- 02:35 - 02:35
people.
- 02:36 - 02:40
So I will be showing that graph here. Okay
- 02:41 - 02:44
So we have here two groups,
- 02:44 - 02:48
the first group I received possible adjuvant and the
- 02:48 - 02:53
other group are received a CPG 7909 a job.
- 02:53 - 02:59
And so the arrows indicate the time of immunization.
- 02:59 - 03:02
So um people who has higher risk
- 03:02 - 03:08
ponds with the vaccine uh increases in LG level.
- 03:08 - 03:15
So here we can see that until nine months in comparison with the classical age event,
- 03:15 - 03:17
the response uh
- 03:17 - 03:23
The response in CPG 7909. Al Joven
- 03:23 - 03:30
is higher compared with the people who just received a possible adjuvants.
- 03:32 - 03:35
So in addition there were no negative impacts on
- 03:35 - 03:40
CD four positive cell count or organ function.
- 03:40 - 03:46
There is also metal systemic and injection site response um
- 03:46 - 03:52
into the people who receive the CPG 7909 ac event.
- 03:53 - 03:56
So another study here is the C. P G. O. D.
- 03:56 - 04:03
N enhances immunization effects on hepatitis B vaccine in age mine.
- 04:04 - 04:07
So the ability of older people or age people
- 04:07 - 04:12
to develop protective immune response is frequently compromise.
- 04:12 - 04:16
So to increase the responsiveness of elderly people to
- 04:16 - 04:20
primary immunization and immune stimulants will be pursued.
- 04:20 - 04:25
So to establish an illicit protective immunity. One method
- 04:26 - 04:30
will be to design vaccine with appropriate at events.
- 04:31 - 04:38
So we have a bar graph here. So we have four groups. So the first group uh the adult
- 04:39 - 04:45
control and then the age control. So here the remaining two groups are also
- 04:46 - 04:47
age.
- 04:47 - 04:48
My cyst.
- 04:48 - 04:52
Here we have two doses. The first dose
- 04:53 - 04:54
I was 10
- 04:54 - 05:03
microgram CPG and the other is a 20 microgram CPG. So here we have to
- 05:03 - 05:08
th one type cytokines, the interleukin 12 and interferon gamma.
- 05:08 - 05:13
So these are measured by ELISA to see if the combination of
- 05:13 - 05:20
CPG and HBs antigen vaccination may improve the th one response.
- 05:20 - 05:22
So weekends he here
- 05:24 - 05:29
that adult mice has higher response of interleukin 12
- 05:29 - 05:33
and interferon gamma compared to the h mice.
- 05:33 - 05:36
But you can also he see here that
- 05:37 - 05:40
where the CPG algae even
- 05:42 - 05:49
The level of interfering and enjoy looking 12 could be as high
- 05:49 - 05:55
as the amount of uh as the like the response of the adult
- 05:56 - 05:57
I'll control.
- 05:58 - 05:59
So
- 06:00 - 06:04
even the mice is already aged.
- 06:05 - 06:12
The response could still be the same or it might be higher like on the adult mice.
- 06:12 - 06:15
Or we can also observe here as the dose
- 06:16 - 06:21
became higher, the response also became higher. So
- 06:22 - 06:23
CPG
- 06:23 - 06:24
O. D. N.
- 06:24 - 06:28
Is suggested that can help the th one cells
- 06:28 - 06:33
response in other mice with a dose dependent impact.
- 06:35 - 06:42
So another C. P. G. O. D. N. Is to be an adjuvant for vaccine in targeting cancer.
- 06:42 - 06:46
Most cancer vaccines aim to produce a large number
- 06:46 - 06:50
of two more specific site a toxic T lymphocytes,
- 06:50 - 06:54
a cellular immunity rather than Hugh moral immunity.
- 06:54 - 06:55
This is
- 06:55 - 07:01
talk to play a key role into more elimination. So C P G O. D N. Increase
- 07:01 - 07:03
that generation of sight.
- 07:03 - 07:06
The toxic CD eight killing besides the target
- 07:06 - 07:11
to more antigens in a pre clinical experiments.
- 07:11 - 07:14
So here is the study to more reactive CD 81
- 07:14 - 07:19
T cell responses after vaccination with a combination of N.
- 07:19 - 07:28
Y E. S. 01 peptide CPG 7909 and Monday Night Association. Read sir. Very well.
- 07:31 - 07:32
Okay here.
- 07:33 - 07:37
So there are there it was analyzed in different times
- 07:38 - 07:48
prior after in the 1st and 2nd cycle. After two years of continued vaccination of N.
- 07:48 - 07:53
Y. E. S. 01. So here the specific T cells were
- 07:54 - 08:00
undetectable prior to the immunization. So after more than three years the
- 08:01 - 08:07
patient's response to the vaccine was every increasing levels of N. Y E. S.
- 08:07 - 08:12
01 specific effect or D cells. So
- 08:12 - 08:13
um
- 08:14 - 08:18
as we can see as it progressed
- 08:18 - 08:20
here until
- 08:21 - 08:26
until three years, there is still detectable. N. Y. S. O. E. S.
- 08:26 - 08:31
01 specific T cells upon the immunization with
- 08:31 - 08:35
the combination of CPG and Mountain night indicating
- 08:35 - 08:38
that the adjuvants had the ability to elicit
- 08:38 - 08:42
a cellular immunological response at measurable level.
- 08:42 - 08:46
So we also have another here figure
- 08:47 - 08:54
This is the pre vaccine and post vaccine. See the 80 cells of the patient.
- 08:54 - 08:57
So we can see see here.
- 08:59 - 09:00
Uh huh.
- 09:01 - 09:06
Vaccination with the results of vaccination week 19 which is after the
- 09:06 - 09:12
cycle one and week 27 after the cycle to off immunization.
- 09:12 - 09:20
So the N Y E S. 01 specific cd eight T cells were still detectable,
- 09:20 - 09:20
mm hmm.
- 09:21 - 09:25
After 30 months of completion of the study.
- 09:25 - 09:30
So here for antigen specific CD eight T cell response were
- 09:30 - 09:35
enhanced and more quickly detectable in prisons immunized with melon A.
- 09:35 - 09:41
PEP to plus monday night with CPG compared to inoculated with melon A.
- 09:41 - 09:45
Type last month and I without CTG.
- 09:45 - 09:50
The outcomes of this study such as the use of C P G seven and seven.
- 09:50 - 09:55
And as an adjuvant to potentially increase the immunogenicity of vaccine
- 09:55 - 09:59
antigens resulting in stronger immune responses
- 09:59 - 10:02
of majority of vaccinated individuals.
- 10:03 - 10:08
So, with all this evidence as that was discussed by the workgroup.
- 10:08 - 10:14
CPG indeed stimulate our immune system and it's a possible adjuvant for vaccines.
- 10:14 - 10:16
Thank you so much for listening